Showing 2634 results
- https://www.novartis.com/news/media-releases/major-study-published-nejm-confirms-novartis-ultibro-breezhaler-superiority-over-seretide-preventing-copd-exacerbationsFLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
- https://www.novartis.com/news/media-releases/novartis-drug-afinitor-recommended-chmp-european-union-approval-treat-select-gi-and-lung-neuroendocrine-tumorsIf approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
- https://www.novartis.com/news/media-releases/novartis-kisqali-reduced-risk-cancer-recurrence-while-maintaining-quality-life-patients-diagnosed-early-breast-cancerPatient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
- https://www.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare-types-periodic-fever-syndromesSubject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
- https://www.novartis.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind-new-launches-long-term-growthNet sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-proposed-100-spin-sandozShareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-le-projet-de-scission-100-de-sandozLes actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
- https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-stimmen-dem-geplanten-100-igen-spin-von-sandoz-zuDie Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
- https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-trotz-verlust-der-exklusivrechte-gleevec-solide-ergebnisse-und-investiert-neueinfuhrungen-zugunsten-langfristigen-wachstumsDer Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
- https://www.novartis.com/news/media-releases/novartis-publishes-updated-2015-segment-financials-reflecting-new-division-structureUpdated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 264
- › Next page